Reply by Authors
J Urol
.
2021 Jun;205(6):1662.
doi: 10.1097/JU.0000000000001592.02.
Epub 2021 Mar 18.
Authors
Dennie Meijer
1
2
,
Hilda A de Barros
3
,
Pim J van Leeuwen
3
,
Yves J L Bodar
1
2
,
Henk G van der Poel
3
,
Maarten L Donswijk
4
,
N Harry Hendrikse
2
5
,
R Jeroen A van Moorselaar
1
,
Jakko A Nieuwenhuijzen
1
3
,
Daniela E Oprea-Lager
2
,
André N Vis
1
3
Affiliations
1
Amsterdam University Medical Center, VU University, Department of Urology, Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.
2
Amsterdam University Medical Center, VU University, Department of Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands.
3
The Netherlands Cancer Institute, Department of Urology, Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.
4
The Netherlands Cancer Institute, Department of Nuclear Medicine, Amsterdam, The Netherlands.
5
Amsterdam University Medical Center, VU University, Department of Clinical Pharmacology and Pharmacy, Amsterdam, The Netherlands.
PMID:
33734856
DOI:
10.1097/JU.0000000000001592.02
No abstract available
Publication types
Comment